CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients

Table 2

Univariate analysis of risk factors for aGvHD and CMV reactivation/infection event(s) in patients post-alloHSCT.

Variable	aGvHD		𝑃 value	CMV absence	CMV presence	𝑃 value
	≤grade I	>grade I		Infection/reactivation until 1 year post-HSCT
Donor/recipient HLA match
Matched	116	40	P <𝟎.𝟎𝟎𝟏	113	36	P =𝟎.𝟎𝟎𝟖
Mismatched at the allele or  low resolution levels up to two mismatches	19	25		20	18
Source of HSCT
PBPC	111	61	P =𝟎.𝟎𝟐𝟗	112	48	𝑃=0.496
BM	24	4		21	6
Type of donor
SIB	65	13	P <𝟎.𝟎𝟎𝟏	61	17	P =𝟎.𝟎𝟕𝟒
MUD	70	52		72	37
Conditioning regimen
RIC	67	28	𝑃=0.450	60	30	𝑃=0.202
Myeloablative	68	37		73	24
Donor CMV IgG
CMV IgG−	38	28	P =𝟎.𝟎𝟑𝟔	36	23	P =𝟎.𝟎𝟓𝟓
CMV IgG+	96	36		96	31
Recipient CMV IgG
CMV IgG−	19	13	𝑃=0.307	24	4	P =𝟎.𝟎𝟕𝟑
CMV IgG+	116	52		109	50
Donor-recipient IgG CMV serology
R−/D−	10	8		15	1
R+/D−	28	20	𝑃=0.159	21	22	P <𝟎.𝟎𝟎𝟏
R−/D+	9	5		9	3
R+/D+	87	31		87	28
R−/D−, R+/D−, R−/D+, R+/D+	106	44	𝑃=0.115	111	32	P <𝟎.𝟎𝟎𝟏
R+/D−	28	20		21	22
Donor/recipient gender
Male to male, female to female, and male  to female	105	54	𝑃=0.572	105	44	𝑃=0.841
Female to male	29	11		28	10
Donor gender
Male	76	40	𝑃=0.543	75	32	𝑃=0.747
Female	58	25		58	22
Recipient gender
Male	76	33	𝑃=0.544	71	27	𝑃=0.747
Female	59	32		62	27
Recipient age
≤16	17	9	𝑃=0.824	20	2	P =𝟎.𝟎𝟒𝟐
>16	118	56		113	52
CMV infection/reactivation event within 1 year post-HSCT
CMV−	97	36	P =𝟎.𝟎𝟐𝟓
CMV+	30	24
aGvHD
aGvHD ≤ grade I				97	30	P =𝟎.𝟎𝟐𝟓
aGvH D>g rade I				36	24
EBV infection/reactivation event within 1 year post HSCT
EBV−	100	42	𝑃=0.204	104	38	𝑃=0.263
EBV+	27	18		29	16
HHV6 infection/reactivation event within 1 year post HSCT
HHV6−	103	50	𝑃=0.835	110	43	𝑃=0.677
HHV6+	24	10		23	11

PBPC: peripheral blood progenitor cells; BM: bone marrow; R: recipient; D: donor; “−”: negative; “+”: positive; ATG: antithymocyte globulin; SIB: HLA-identical siblings; MUD: unrelated donors; RIC: reduced intensity conditioning.